Global healthcare company Abbott (NYSE:ABT) on Saturday announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios to treat heart rhythm disorders.

The data presented at Heart Rhythm Society 2026 in Chicago include six-month results from the FlexPulse IDE study, which examines treating complex atrial fibrillation (AFib) cases with the TactiFlex Duo Ablation Catheter, Sensor Enabled, as well as new clinical evidence for posterior wall ablation with the Volt PFA System. Data were also presented for Abbott's ASCEND CSP IDE trial for the company's investigational UltiSynq CSP implantable cardioverter-defibrillator (ICD) lead, as well as a first-in-human evaluation of the LEAP2 chronic early feasibility trial for the investigational AVEIR CSP leadless pacemaker system.

According to the company, new six-month data from the FlexPulse IDE study provide early insights showing positive patient outcomes with Abbott's TactiFlex Duo Ablation Catheter, Sensor Enabled, and confirm the strong safety and efficacy profile seen in the CE Mark study for treating complex AFib cases. The FlexPulse IDE study was designed to secure US Food and Drug Administration (FDA) approval for the TactiFlex Duo. The catheter received CE Mark in Europe earlier this year.

Late-breaking six-month data from the Volt CE Mark Extension Cohort trial demonstrated positive outcomes for patients in which the posterior wall of the heart was treated in addition to the standard treatment. The Volt PFA System secured FDA approval and CE Mark in Europe last year.

Results from two late-breaking clinical trials evaluated Abbott's investigational leadless and traditional pacing/defibrillation CSP technologies designed to deliver left bundle branch pacing (LBBP), an approach intended to more closely replicate the heart's natural electrical activation. Both data presentations were simultaneously published in Heart Rhythm. The ASCEND CSP IDE trial evaluated the investigational high-voltage UltiSynq CSP ICD lead designed to be implanted in the left bundle branch (LBB) area or the right ventricle to deliver both pacing and defibrillation. The three-month data show UltiSynq CSP successfully met the study's pre-specified primary safety and effectiveness endpoints.